PAR-20-292 - NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) is used for the submission of applications to the following Notices of Special Interest (NOSIs)
On This Page: 4
Active NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|---|---|---|---|---|
Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer | NOT-CA-22-085 | NCI | May 5, 2022 | Jul 5, 2027 | K22, R01, K08, K01, R21, R03, K99/R00 |
Expired NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|---|---|---|---|---|
Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity | NOT-CA-22-001 | NCI NHLBI | Nov 4, 2021 | Nov 6, 2024 | R01, R03, R21, P01 |
Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention | NOT-CA-21-121 | NCI | Oct 4, 2021 | Sep 8, 2024 | K22, K08, R15, R01, R21, K99/R00, |
Notice of Special Interest (NOSI): Advancing the development of tumor site-activated small molecules | NOT-CA-21-101 | NCI | Aug 16, 2021 | Jan 8, 2024 | R01, R15, R21 |